Home Page


Frequent Questions

Flowchart of Diagnosis

Latest Research

Clinical Trials

News 2015

News 2014

News 2013

News 2012

News 2011

News 2010

News 2009

News 2008

News 2007

News 2006

News 2005

News 2004

Early History

Contact Information



Privacy Policy and Confidentiality

Advertising and Editorial Policy








Clinical Trials

We receive numerous inquiries about information regarding clinical trials. In turn, we also receive requests from those conducting these trials to place the information and links on our site in order to improve patient enrollment in their studies. This page serves as a guide to updated information on this subject; therefore, if you know of one that we do not have listed, or you wish to see your clinical trial announced or promoted, please feel welcome to contact us.

A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma

Quick Overview: This clinical trial is designed to evaluate the effectiveness and collect additional safety information on Ultratrace® Iobenguane I 131 for the treatment of relapsed/refractory (to other treatment) malignant pheochromocytoma and paraganglioma. The purpose of this trial is to test the use of Ultratrace® iobenguane I 131 as a treatment for pheochromocytoma and paraganglioma type cancer. This Phase II study will help determine primarily if using the drug reduces the amount of blood pressure medication being taken as a result of the cancer and secondarily to determine such things as the effectiveness of the study drug in treating the cancer, additional safety measures, and to assess if the drug helps the quality of life and use of pain medication. All subjects will receive an imaging dose with scans followed by two therapy doses that are given 3 months apart.

Detailed Overview and Link:
Clinical Trial Phase II Ultratrace Iobenguane I 131 (MIBG)

Oxford Outcomes Research Study
Quick Overview: Oxford Outcomes is conducting a qualitative research study involving interviews with pheo/para patients in order to evaluate the clarity, relevance, and comprehensiveness of two questionnaires (one cancer specific and one pheo/para specific), and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.

Detailed Overview and Link:
Oxford Outcomes Inc

Molecular Insight Pharmaceuticals, Inc. – Clinical Trial: Malignant Pheo, Paraganglioma
Quick Overview: This clinical trial benefits patients with certain types of pheochromocytoma, paraganglioma or metastatic carcinoid tumors. Molecular Insight Pharmaceuticals, Inc is located in Cambridge, MA, USA. The actual study is being conducted at various location. Please see the link below for more information about the clinical trial and locations.

Detailed Overview and Link:
Molecular Insight Pharmaceuticals Clinical Trials

Cornell Medical Center – Study: Focuses on patients with symptoms of pheochromocytoma but no evidence of having the illness.
Quick Overview: This study benefits patients who have the severe symptoms that are suggestive of pheochromocytoma but who don't have evidence to confirm a diagnosis. Dr. Sam Mann of the New York Presbyterian Hospital in New York is in charge of this study.

Detailed Overview and Link:
Cornell Medical Center Study